VIR — Vir Biotechnology, Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1706431 ·
Last close
$10.66
Market Cap
$1.80B
52W High
$11.94
52W Low
$4.82
ADV30
2,088,747
Next earnings
2026-11-04
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 238,935,000 | 238,935,000 | 73,467,000 | 80,080,000 | 1,214,806,000 | 278,729,000 | 232,313,000 |
| Mar 2026 | -41,000 | — | -132,290,000 | -125,695,000 | 1,025,585,000 | 274,161,000 | 212,820,000 |
| Dec 2025 | 63,760,000 | 63,734,000 | -47,921,000 | -42,923,000 | 1,002,823,000 | 232,185,000 | 237,547,000 |
| Sep 2025 | -65,000 | -54,000 | -173,443,000 | -163,141,000 | 1,019,453,000 | 170,084,000 | 223,355,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-202,506,000
Investing CF
$-58,210,000
Financing CF
$242,040,000
CapEx
$-1,087,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.86
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,243,386,000
Inventory
—
Receivables
—
ST Investments
$253,997,000
EBIT TTM
$-280,187,000
Pretax Income TTM
$-251,299,000
Interest Exp TTM
—
Analysts
9
Yahoo Snapshot (yfinance, live)
Total Revenue
$303,227,008
EBITDA
$-267,958,000
Free Cash Flow
$-38,885,876
Enterprise Value
$1,357,621,504
Total Cash
$532,726,016
Total Debt
$93,274,000
Shares Out
169,215,958
Trailing EPS
$-1.77
Book Value
$5.04
ROE
-26.1%
ROA
-14.5%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 66,520,000 | -479,510,000 | -437,987,000 | 1,002,823,000 | 237,547,000 | 765,276,000 | -391,781,000 |
| Dec 2024 | 63,712,000 | -552,170,000 | -521,960,000 | 1,398,813,000 | 248,428,000 | 1,150,385,000 | -446,352,000 |
| Dec 2023 | 39,494,000 | -670,746,000 | -615,061,000 | 1,919,060,000 | 328,824,000 | 1,590,236,000 | -778,785,000 |
| Dec 2022 | 1,580,472,000 | 833,068,000 | 515,837,000 | 2,802,088,000 | 724,125,000 | 2,077,963,000 | 1,663,253,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-2.49
Max Pain — expiry 2026-10-16
max pain strike: $10.00 · spot: $10.66 · call oi: 2,766 · put oi: 848
Expected Move to 2026-10-16:
±$1.05
(9.85%) —
implied range
$9.61 –
$11.71
· ATM straddle on $11.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| NVAX | NOVAVAX INC | $1.75B | $10.63 | — |
| MESO | MESOBLAST LTD | $1.96B | $15.12 | — |
| RXRX | RECURSION PHARMACEUTICALS, INC. | $2.00B | $3.74 | — |
| COAG | Hemab Therapeutics Holdings, Inc. | $1.62B | $34.74 | — |
| KOD | Kodiak Sciences Inc. | $2.03B | $32.35 | — |
News headlines (Yahoo Finance, 1h cache)
Vir Biotechnology to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
2026-08-31 20:05 · Yahoo
Vir Biotechnology (VIR) Q2 2026 Earnings Call Transcript
2026-08-12 21:28 · Yahoo
Vir Biotechnology Inc (VIR) (Q2 2026) Earnings Call Highlights: 88% HDV Cure Rate and a $1B ...
2026-08-06 05:08 · Yahoo
Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2026 Financial Results
2026-08-05 20:05 · Yahoo
Vir Biotechnology (VIR) Could Be 60% Undervalued On CFO Transition
2026-08-01 00:14 · Yahoo
Vir Biotechnology to Host Conference Call for Second Quarter 2026 Financial Results
2026-07-22 20:05 · Yahoo
Vir Biotechnology, Inc. Q2 2026 Earnings Call Summary
2026-08-06 12:30 · Yahoo
Vir Biotechnology Q2 Earnings Call Highlights
2026-08-06 07:03 · Yahoo
Vir Biotechnology Announces Chief Financial Officer Transition
2026-07-24 12:30 · Yahoo
Brii Bio Announces Topline End-of-Treatment Data from Phase 2b ENRICH and ENHANCE Studies for the Treatment of Chronic Hepatitis B
2026-07-03 00:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.